Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trevena, a pharmaceutical company focused on the discovery of G-protein coupled receptor (GPCR) biased ligands, has received a grant of $205,000 from the Michael J. Fox Foundation (MJFF) for Parkinson's disease research.
Subscribe to our email newsletter
According to the company, the one-year Target Validation Funding Award will support pathway validation experiments to show the efficacy of novel biased ligands to the delta-opioid receptor in treating Parkinson’s disease.
Based on scientific evidence, Trevena suggests that its proprietary biased ligands avoid the on-target mediated convulsions found with traditional delta-opioid agonists, offering the possibility of a new approach to treat Parkinson’s disease symptoms.
Trevena Chief Scientific Officer Michael Lark said the foundation has established itself in the field of Parkinson’s disease treatments.
"We are thrilled to become part of that scientific community and to apply our novel scientific approach to address the burden of this disease for patients and their families," Lark added.